ReViral
Stevenage
About ReViral
ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $121.0M
- Funding stage: M&A
- Last round: Series C (Aug 2020)
- Website: reviral.co.uk
- Phone: 44 29 2078 1795
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/reviral-30662 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.